Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia
暂无分享,去创建一个
T. Naoe | T. Yamauchi | T. Taube | K. Ando | Y. Miyazaki | H. Kiyoi | T. Hata | Yukio Kobayashi | T. Sakura | Akiko Harada | Aiko Watabe | Y. Kobayashi
[1] J. Zuber,et al. Efficacy and Mechanism of Action of Volasertib, a Potent and Selective Inhibitor of Polo-Like Kinases, in Preclinical Models of Acute Myeloid Leukemia , 2015, The Journal of Pharmacology and Experimental Therapeutics.
[2] J. Cortes,et al. New treatment for acute myelogenous leukemia , 2015, Expert opinion on pharmacotherapy.
[3] K. Döhner,et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. , 2014, Blood.
[4] S. Sleijfer,et al. Tyrosine kinase inhibitors and QTc intervals: A class effect. , 2014 .
[5] K. Yeh,et al. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies , 2014, British Journal of Cancer.
[6] A. Awada,et al. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. , 2012, European journal of cancer.
[7] K. Kolaja,et al. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes , 2011, Nature Reviews Drug Discovery.
[8] H. Kantarjian,et al. Questions regarding frontline therapy of acute myeloid leukemia , 2010, Cancer.
[9] K. Strebhardt,et al. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy , 2010, Nature Reviews Drug Discovery.
[10] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[11] A. Ray,et al. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics , 2010, Expert opinion on investigational drugs.
[12] Christian Bailly,et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. , 2009, Blood.
[13] P. Schöffski. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. , 2009, The oncologist.
[14] G. Adolf,et al. BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity , 2009, Clinical Cancer Research.
[15] C. Craddock,et al. Biology and management of relapsed acute myeloid leukaemia , 2005, British journal of haematology.
[16] Jun Yoshimatsu,et al. Polo-like kinases (Plks) and cancer , 2005, Oncogene.
[17] R. Stone,et al. Acute myeloid leukemia. , 2012, Hematology. American Society of Hematology. Education Program.
[18] Elizabeth H. Wood,et al. The National Comprehensive Cancer Network (NCCN). , 2004 .
[19] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] D. Longo,et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. , 1997, Biochemical and biophysical research communications.